Highlights Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
21.26 ^USD	-5.68%		-8.08%	-21.90%

07/05	Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates	MT
07/05	Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates	07/05	MT
Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency	26/03	MT
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency	26/03	CI
Health Care Down as Viking Move Rattles Novo Shares -- Health Care Roundup	28/02	DJ
Beam Therapeutics Shares Jump on Surprise Q4 Profit	27/02	MT
Beam Therapeutics Reports Surprise Q4 Profit; Shares Jump in Early Trading	27/02	MT
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02	CI
Beam Therapeutics Inc. Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones	08/01	CI
Beam Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Eli Lilly to Acquire Beam Therapeutics' Opt-In Rights to Verve Therapeutics' Cardiovascular Programs	31/23/31	MT
Eli Lilly, Beam Sign Initial $250 Million Deal for Verve Rights	31/23/31	MT
Beam Therapeutics to Sell Rights in Verve Licensing Deal to Lilly for $250 Million Upfront	31/23/31	DJ
Eli Lilly and Company Agree to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease	31/23/31	CI
Beam, Inc. Announces Plans to Advance Clinical Trials and Programs	19/23/19	CI
Beam Therapeutics Inc. Presents Preclinical Data Highlighting Utility of Beam-302 to Correct an Alpha-1 Antitrypsin Deficiency Disease-Causing Mutation	07/23/07	CI
Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08	CI
Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
BEAM THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	28/23/28	AQ
Beam Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto

January 31, 2024 at 12:51 am IST